Methamphetamine Addiction From Basic Science to Treatment pptx

Methamphetamine Addiction

Methamphetamine Addiction

From Basic Science to Treatment

Edited by

John M. Roll

Richard A. Rawson

Walter Ling

Steven Shoptaw

The Guilford Press

New York London

© 2009 The Guilford Press

A Division of Guilford Publications, Inc.

72 Spring Street, New York, NY 10012

www.guilford.com

All rights reserved

No part of this book may be reproduced, translated, stored in a retrieval

system, or transmitted, in any form or by any means, electronic, mechanical,

photocopying, microfilming, recording, or otherwise, without written permission

from the Publisher.

Printed in the United States of America

This book is printed on acid-free paper.

Last digit is print number: 9 8 7 6 5 4 3 2 1

The authors have checked with sources believed to be reliable in their efforts to

provide information that is complete and generally in accord with the standards

of practice that are accepted at the time of publication. However, in view of the

possibility of human error or changes in medical sciences, neither the authors,

nor the editor and publisher, nor any other party who has been involved in the

preparation or publication of this work warrant that the information contained

herein is in every respect accurate or complete, and they are not responsible for

any errors or omissions or the results obtained from the use of such information.

Readers are encouraged to confirm the information contained in this book with

other sources.

Library of Congress Cataloging-in-Publication Data

Methamphetamine addiction: from basic science to treatment / editors,

John M. Roll ... [et al.].

p. cm.

Includes bibliographical references and index.

ISBN 978-1-60623-252-1 (hardcover: alk. paper)

1. Methamphetamine abuse. 2. Methamphetamine abuse—Treatment.

3. Methamphetamine. I. Roll, John M.

RC568.A45M483 2009

616.86′4—dc22

2009003203

With thanks to Marshall, MaryAnn, and Joy

—J. M. R.

To Maya and Jackson

—R. A. R.

For my mother

—W. L.

For all those affected by this disorder

—S. S.

vii

About the Editors

John M. Roll, PhD, is Professor and Associate Dean for Research at Washington

State University College of Nursing in Spokane, and the Director of its Pro￾gram of Excellence in the Addictions. He has held postdoctoral fellowship posi￾tions at the University of Vermont and the University of Michigan and faculty

appointments at Wayne State University and the University of California, Los

Angeles. In 2006, Dr. Roll was elected a Fellow of the American Psychological

Association. He is President of the American Psychological Association’s Divi￾sion on Psychopharmacology and Substance Abuse and was a vice-chairman of

the Washington State Governor’s Council on Substance Abuse. He has received

research funding from federal, state, and local sources as well as foundation and

industry support. Dr. Roll has served as a member of the editorial boards of the

Journal of the Experimental Analysis of Behavior and the Journal of Applied

Behavior Analysis.

Richard A. Rawson, PhD, is Associate Director of the UCLA Integrated Sub￾stance Abuse Programs, one of the foremost substance abuse research groups

in the United States and worldwide, and Professor-in-Residence in the Depart￾ment of Psychiatry and Biobehavioral Sciences at the David Geffen School of

Medicine at the University of California, Los Angeles. Dr. Rawson oversees

clinical trials on pharmacological and psychosocial addiction treatments. He

has led addiction research and training projects for the United Nations, the

World Health Organization (WHO), and the U.S. State Department that export

science-based knowledge to many parts of the world. Dr. Rawson’s research on

methamphetamine is extensive, and from 1996 to 1999 he was a member of the

Federal Methamphetamine Advisory Group for former U.S. Attorney General

Janet Reno. He is currently principal investigator of both the Pacific South￾west Addiction Technology Transfer Center funded by the Substance Abuse and

Mental Health Services Administration and the UCLA Drug Abuse Research

Training Grant funded by the National Institute on Drug Abuse (NIDA). Dr.

Rawson has published 2 books, 30 book chapters, and more than 200 peer￾reviewed articles and has conducted over 1,000 workshops, presentations, and

training sessions.

viii About the Editors

Walter Ling, MD, is a board-certified neurologist and psychiatrist, a Profes￾sor-in-Residence of Psychiatry at the David Geffen School of Medicine at the

University of California, Los Angeles, and Director of the UCLA Integrated

Substance Abuse Programs. He is a consultant for numerous local, national, and

international private and public agencies. Dr. Ling serves as Principal Investiga￾tor of the Pacific Node of the NIDA Clinical Trials Network, designed to bring

cutting-edge findings from treatment research to practice in community treat￾ment programs throughout the United States. He also does consulting and col￾laborative work with the U.S. Department of State, the United Nations Office of

International Narcotics Affairs, and the WHO.

Steven Shoptaw, PhD, is Professor of Family Medicine and of Psychiatry and

Biobehavioral Sciences at the David Geffen School of Medicine at the Univer￾sity of California, Los Angeles. Dr. Shoptaw’s research involves developing and

implementing efficacious treatments for individuals with various drug depen￾dence problems, particularly for those with stimulant dependence and risks for

HIV infection and other health care problems. He has published over 120 sci￾entific articles on these topics, including a 2006 treatment manual coauthored

with Cathy Reback and Richard A. Rawson, Getting Off: A Behavioral Treat￾ment Intervention for Gay and Bisexual Male Methamphetamine Users. In

addition to clinical and research work, Dr. Shoptaw also volunteers as Execu￾tive Director for Safe House, a facility he started that provides high-tolerance

emergency, transitional, and permanent housing for 26 persons living with HIV/

AIDS, mental illness, and/or chemical dependency, who are also homeless or at

risk for homelessness.

ix

Contributors

Nathan M. Appel, PhD, Division of Pharmacotherapies and Medical

Consequences of Drug Abuse, National Institute on Drug Abuse,

Bethesda, Maryland

Michelle A. Bholat, MD, Department of Family Medicine, David Geffen

School of Medicine, University of California, Los Angeles,

Los Angeles, California

Ahmed Elkashef, PhD, Division of Pharmacotherapies and Medical

Consequences of Drug Abuse, National Institute on Drug Abuse,

Bethesda, Maryland

David Farabee, PhD, UCLA Integrated Substance Abuse Programs, Semel

Institute for Neuroscience and Human Behavior, David Geffen School of

Medicine, University of California, Los Angeles, Los Angeles, California

Annette E. Fleckenstein, PhD, Pharmacology and Toxicology Department,

College of Pharmacy, University of Utah, Salt Lake City, Utah

Suzette Glasner-Edwards, PhD, UCLA Integrated Substance Abuse Programs,

Semel Institute for Neuroscience and Human Behavior, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Glen R. Hanson, DDS, Pharmacology and Toxicology Department,

College of Pharmacy, University of Utah, Salt Lake City, Utah

Angela Hawken, PhD, UCLA Integrated Substance Abuse Programs, Semel

Institute for Neuroscience and Human Behavior, David Geffen School of

Medicine, University of California, Los Angeles, Los Angeles, California

Keith Heinzerling, MD, MPH, Department of Family Medicine,

David Geffen School of Medicine, University of California, Los Angeles,

Los Angeles, California

x Contributors

Chris-Ellyn Johanson, PhD, Department of Psychiatry and Behavioral

Neurosciences, Wayne State University, Chicago, Illinois

William D. King, MD, Department of Family Medicine, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Evan Landstrom, Department of Family Medicine, David Geffen School of

Medicine, University of California, Los Angeles, Los Angeles, California

Sarah Lefkowith, Department of Family Medicine, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Walter Ling, MD, UCLA Integrated Substance Abuse Programs,

Semel Institute for Neuroscience and Human Behavior, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Edythe D. London, PhD, UCLA Neuropsychiatric Institute, David Geffen

School of Medicine, University of California, Los Angeles,

Los Angeles, California

Jane C. Maxwell, PhD, Addiction Research Institute, University of Texas at

Austin, Austin, Texas

Larissa Mooney, MD, UCLA Integrated Substance Abuse Programs,

Semel Institute for Neuroscience and Human Behavior, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Jagoda Pasic, MD, PhD, Department of Psychiatry and Behavioral Sciences,

University of Washington at Harborview Medical Center, Seattle, Washington

Doris Payer, BS, UCLA Neuropsychiatric Institute, David Geffen School of

Medicine, University of California, Los Angeles, Los Angeles, California

Richard A. Rawson, PhD, UCLA Integrated Substance Abuse Programs,

Semel Institute for Neuroscience and Human Behavior, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Richard Ries, MD, Department of Psychiatry and Behavioral Sciences,

University of Washington at Harborview Medical Center, Seattle, Washington

John M. Roll, PhD, College of Nursing, Washington State University,

Spokane, Washington

Craig R. Rush, PhD, College of Medicine, University of Kentucky,

Lexington, Kentucky

Beth A. Rutkowski, MPH, UCLA Integrated Substance Abuse Programs,

Semel Institute for Neuroscience and Human Behavior, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Contributors xi

Charles R. Schuster, PhD, Department of Psychiatry and Behavioral

Neurosciences, Wayne State University, Chicago, Illinois

Steven Shoptaw, PhD, Department of Family Medicine, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

Sharon Sowell, BA, Department of Clinical Psychology, Washington State

University, Spokane, Washington

William W. Stoops, PhD, Department of Behavioral Science, College of

Medicine, University of Kentucky, Lexington, Kentucky

Linda J. Thompson, MA, Greater Spokane Substance Abuse Council,

Spokane Valley, Washington

Gregory D. Victorianne, BA, Department of Family Medicine,

David Geffen School of Medicine, University of California, Los Angeles,

Los Angeles, California

Frank J. Vocci, PhD, Friends Research Institute, Baltimore, Maryland

Matthew Worley, BA, Department of Family Medicine, David Geffen School

of Medicine, University of California, Los Angeles, Los Angeles, California

xiii

Contents

Chapter 1. Introduction 1

John M. Roll, Richard A. Rawson, Steven Shoptaw,

and Walter Ling

Chapter 2. Epidemiology of Methamphetamine Use: A Global Perspective 6

Beth A. Rutkowski and Jane C. Maxwell

Chapter 3. Basic Neuropharmacological Mechanisms

of Methamphetamine

30

Glen R. Hanson and Annette E. Fleckenstein

Chapter 4. Methamphetamine and the Brain:

Findings from Brain Imaging Studies

61

Doris Payer and Edythe D. London

Chapter 5. Behavioral Pharmacology and Psychiatric Consequences

of Methamphetamine

92

Craig R. Rush, William W. Stoops, and Walter Ling

Chapter 6. Medical Effects of Methamphetamine Use 117

Larissa Mooney, Suzette Glasner-Edwards,

Richard A. Rawson, and Walter Ling

Chapter 7. Public Health Issues Surrounding

Methamphetamine Dependence

143

Steven Shoptaw, William D. King, Evan Landstrom,

Michelle A. Bholat, Keith Heinzerling,

Gregory D. Victorianne, and John M. Roll

xiv Contents

Chapter 8. Methamphetamine and Crime 157

David Farabee and Angela Hawken

Chapter 9. Effects of Methamphetamine on Communities 172

Linda J. Thompson, Sharon Sowell, and John M. Roll

Chapter 10. Psychosocial and Behavioral Treatment

of Methamphetamine Dependence

185

Steven Shoptaw, Richard A. Rawson, Matthew

Worley, Sarah Lefkowith, and John M. Roll

Chapter 11. Pharmacological Treatment of Methamphetamine Addiction 202

Frank J. Vocci, Ahmed Elkashef, and Nathan M. Appel

Chapter 12.Treatment of Methamphetamine Addiction That Co-Occurs

with Serious Mental Illness

230

Jagoda Pasic and Richard Ries

Chapter 13. Conclusion 246

Charles R. Schuster, Chris-Ellyn Johanson,

and John M. Roll

Index 251

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 Chapter 9 Chapter 10 Chapter 11 Chapter 12 Chapter 13